lymphoma cell line jijoye Search Results


lymphoma cell line jijoye  (ATCC)
97
ATCC lymphoma cell line jijoye
Comparison of gp350 amino acid sequences. The amino acid sequence (amino acids 1 to 504) of the gp350 protein of <t>the</t> <t>EBV-1</t> strain Akata is shown. The known CD21 binding regions are underlined. The amino acid differences in gp350 of the EBV-2 strain <t>Jijoye</t> are in bold above the EBV-1 sequence.
Lymphoma Cell Line Jijoye, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/TF-1/pmc07269432-275-3-9
Average 97 stars, based on 1 article reviews
lymphoma cell line jijoye - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
burkitt lymphoma cells  (ATCC)
94
ATCC burkitt lymphoma cells
Comparison of gp350 amino acid sequences. The amino acid sequence (amino acids 1 to 504) of the gp350 protein of <t>the</t> <t>EBV-1</t> strain Akata is shown. The known CD21 binding regions are underlined. The amino acid differences in gp350 of the EBV-2 strain <t>Jijoye</t> are in bold above the EBV-1 sequence.
Burkitt Lymphoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/P3HR-1/pmc12616731-460-5-42
Average 94 stars, based on 1 article reviews
burkitt lymphoma cells - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
burkitt lymphoma cell lines  (ATCC)
98
ATCC burkitt lymphoma cell lines
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
Burkitt Lymphoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/Daudi/pm15467034-66-10-22
Average 98 stars, based on 1 article reviews
burkitt lymphoma cell lines - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
ebv type 2 burkitt s lymphoma jijoye cell line  (ATCC)
94
ATCC ebv type 2 burkitt s lymphoma jijoye cell line
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
Ebv Type 2 Burkitt S Lymphoma Jijoye Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/Jiyoye/us08623647-232-0-24
Average 94 stars, based on 1 article reviews
ebv type 2 burkitt s lymphoma jijoye cell line - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
burkitt lymphoma derived jijoye  (ATCC)
93
ATCC burkitt lymphoma derived jijoye
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
Burkitt Lymphoma Derived Jijoye, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/Jiyoye%3B+Burkitt's+Lymphoma%3B+Human/us07790152-190-129-132
Average 93 stars, based on 1 article reviews
burkitt lymphoma derived jijoye - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier
bamhi  (New England Biolabs)
99
New England Biolabs bamhi
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
Bamhi, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/BamHI/custom%40r0136%4023657834
Average 99 stars, based on 1 article reviews
bamhi - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
ecori  (New England Biolabs)
99
New England Biolabs ecori
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
Ecori, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/EcoRI/custom%40r0101%4023657834
Average 99 stars, based on 1 article reviews
ecori - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
burkitt lymphoma  (ATCC)
94
ATCC burkitt lymphoma
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
Burkitt Lymphoma, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/MC116/pm16082248-34-6-37
Average 94 stars, based on 1 article reviews
burkitt lymphoma - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
ddx0160p-100  (Bio-Techne corporation)
90
Bio-Techne corporation ddx0160p-100
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
Ddx0160p 100, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/ddx0160p-100/bio-techne+corporation___ddx0160p-100
Average 90 stars, based on 1 article reviews
ddx0160p-100 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
t4 dna ligase  (New England Biolabs)
99
New England Biolabs t4 dna ligase
Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive <t>Burkitt</t> <t>lymphoma</t> cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.
T4 Dna Ligase, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lymphoma+cell+line+jijoye/T4+DNA+Ligase/custom%40m0202%4023657834
Average 99 stars, based on 1 article reviews
t4 dna ligase - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

Image Search Results


Comparison of gp350 amino acid sequences. The amino acid sequence (amino acids 1 to 504) of the gp350 protein of the EBV-1 strain Akata is shown. The known CD21 binding regions are underlined. The amino acid differences in gp350 of the EBV-2 strain Jijoye are in bold above the EBV-1 sequence.

Journal: Journal of Virology

Article Title: CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells

doi: 10.1128/JVI.00428-20

Figure Lengend Snippet: Comparison of gp350 amino acid sequences. The amino acid sequence (amino acids 1 to 504) of the gp350 protein of the EBV-1 strain Akata is shown. The known CD21 binding regions are underlined. The amino acid differences in gp350 of the EBV-2 strain Jijoye are in bold above the EBV-1 sequence.

Article Snippet: The EBV-2-positive Burkitt’s lymphoma cell line Jijoye (P-2003, P-3J; ATCC, Manassas, VA) and the EBV-negative cell line BL41 (gift of J. Sixbey, St. Jude Children's Research Hospital) were maintained in complete RPMI at 37°C and 5% CO 2 .

Techniques: Comparison, Sequencing, Binding Assay

Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive Burkitt lymphoma cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.

Journal: Journal of the National Cancer Institute

Article Title: Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

doi: 10.1093/jnci/djh271

Figure Lengend Snippet: Fig. 2. Depsipeptide, apoptosis, and proliferation of Epstein-Barr virus (EBV)– positive lymphoblastoid cell lines (LCLs) and EBV-negative and EBV-positive Burkitt lymphoma cell lines. A–C) Cell viability and depsipeptide. A) Assess- ment of cell viability by flow cytometry with Annexin V–fluorescein isothio- cyanate (FITC) and propidium iodide staining of EBV-positive LCLs 72 hours after a 4-hour 500 nM depsipeptide treatment. Percentages of viable, apoptotic, and necrotic cells are shown. Results from a single representative LCL (PA cells) are shown and are similar to those of two LCLs (C7M3 and RM) tested. B, C) Viability of EBV-positive and EBV-negative Burkitt lymphoma cell lines, respectively, were relatively unaffected by depsipeptide. D–I) Cell proliferation. Bar cells incubated in standard growth medium; bar – cells incubated with mitomycin C to inhibit incorporation of thymidine. Depsipeptide (500 nM) inhibited the proliferation (incorporation of [3H]thymidine, expressed as counts per minute [CPM]) of EBV-positive LCLs 72 hours after treatment (D); the proliferation of EBV-positive (Raji) and EBV-negative (BL41) Burkitt lym- phoma cell lines, respectively, was unaffected (E, F). Absolute number of viable cells remained fixed in depsipeptide-treated EBV-positive LCL cultures (G), whereas the total number of viable cells in EBV-positive and EBV-negative Burkitt lymphoma cell cultures increased over a 96-hour period (H, I). Data in panels D–I represent the mean of three replicate experiments with 95% confi- dence intervals.

Article Snippet: EBVnegative Burkitt lymphoma cell lines (BL-41 and Ramos) and EBV-positive Burkitt lymphoma cell lines (Raji, Daudi, and Jijoye) were obtained from the American Type Culture Collection (Manassas, VA).

Techniques: Virus, Cytometry, Staining, Incubation